Oxaliplatin and axonal Na+ channel function in vivo
- PMID: 16899592
- DOI: 10.1158/1078-0432.CCR-06-0694
Oxaliplatin and axonal Na+ channel function in vivo
Abstract
Purpose: The aim of the study was to investigate the pathophysiology of oxaliplatin-induced neurotoxicity using clinical nerve excitability techniques that provide information about axonal ion channel function.
Experimental design: Excitability studies were combined with standard nerve conduction studies and clinical assessment in 22 patients undergoing treatment with oxaliplatin.
Results: Excitability studies recorded before and immediately after oxaliplatin infusion for 89 treatment cycles revealed significant increases in refractoriness and relative refractory period postinfusion in all patients, consistent with an effect of oxaliplatin on axonal Na(+) channels. However, those patients that developed chronic neuropathy had significantly greater changes. Following cessation of oxaliplatin treatment, 41% of patients had persistent symptoms and nerve conduction abnormalities consistent with the development of chronic neuropathy.
Conclusion: The present study provides evidence that oxaliplatin-induced neurotoxicity is mediated through an effect on axonal Na(+) channels. Clinical nerve excitability techniques may prove beneficial in monitoring for early signs of neurotoxicity and in the assessment of future prophylactic therapies.
Similar articles
-
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10. Brain. 2009. PMID: 19745023
-
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.J Clin Oncol. 2009 Mar 10;27(8):1243-9. doi: 10.1200/JCO.2008.19.3425. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164207
-
Oxaliplatin-induced neurotoxicity and the development of neuropathy.Muscle Nerve. 2005 Jul;32(1):51-60. doi: 10.1002/mus.20340. Muscle Nerve. 2005. PMID: 15880395
-
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. doi: 10.1016/j.critrevonc.2006.01.001. Epub 2006 Jun 27. Crit Rev Oncol Hematol. 2006. PMID: 16806962 Review.
-
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33. doi: 10.1053/sonc.2002.35525. Semin Oncol. 2002. PMID: 12422305 Review.
Cited by
-
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.PLoS One. 2011 Apr 8;6(4):e18469. doi: 10.1371/journal.pone.0018469. PLoS One. 2011. PMID: 21494615 Free PMC article. Clinical Trial.
-
Broad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy.Pain. 2023 Nov 1;164(11):2581-2595. doi: 10.1097/j.pain.0000000000002963. Epub 2023 Aug 7. Pain. 2023. PMID: 37556385 Free PMC article.
-
Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?Neuroscientist. 2022 Apr;28(2):103-120. doi: 10.1177/1073858420981866. Epub 2020 Dec 21. Neuroscientist. 2022. PMID: 33345706 Free PMC article.
-
A novel path to chronic proprioceptive disability with oxaliplatin: Distortion of sensory encoding.Neurobiol Dis. 2016 Nov;95:54-65. doi: 10.1016/j.nbd.2016.07.004. Epub 2016 Jul 7. Neurobiol Dis. 2016. PMID: 27397106 Free PMC article.
-
Oxaliplatin: a review in the era of molecularly targeted therapy.Curr Oncol. 2011 Jan;18(1):18-25. doi: 10.3747/co.v18i1.708. Curr Oncol. 2011. PMID: 21331278 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
